Dose study of two targeted drugs for recurrent ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Your cancer diagnosis is confirmed on pathology, and your tumor type fits the trial’s specific subtypes
- Your cancer has returned after prior treatment (and you meet the trial’s “platinum-resistant” timing rule if applicable)
- You can have at least one biopsy for tumor testing (and Part II requires paired tumor biopsies)
- Your body can safely tolerate treatment: blood counts, kidney function, and liver tests must meet set minimums
- You can take oral study capsules/tablets without crushing or opening them
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial studies whether a targeted treatment, chosen based on tumor biology, can help people with recurrent ovarian cancer. You may be asked to give a tumor biopsy so researchers can analyze specific “signal” activity in your cancer.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
This study tests a new drug called TUB-040 for uterine cancer that has come back or not responded to previous treatments. The drug targets a protein on cancer cells and delivers a chemotherapy directly to them. This might help shrink tumors or slow the cancer's growth.
Hear when a new Recurrent Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.